204449-17-2

Upstream product

• 541-47-9 3-Methylbutenoic acid 
• 106-53-6 para-bromobenzenethiol 

Downstream Products

• 224950-84-9 4-[1-(2,2-dimethoxy-ethyl)-2-(2,2-dimethyl-4-p-tolyl-2H-thiochromen-6-yl)-vinyl]-benzoic acid ethyl ester 
• 224950-93-0 4-{1-[1-[2,2-Dimethyl-4-(5-methyl-thiophen-2-yl)-2H-thiochromen-6-yl]-meth-(E)-ylidene]-3,3-dimethoxy-propyl}-benzoic acid ethyl ester 
• 224950-82-7 6-bromo-2,2-dimethyl-4-p-tolyl-thiochroman-4-ol 
• 204449-19-4 6-bromo-2,2-dimethyl-4-p-tolyl-2H-thiochromene 
• 224950-80-5 3-(4-bromo-phenylsulfanyl)-3-methyl-butyryl chloride 

Relevant academic research and scientific papers

Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors

Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RARγ agonist retinoids, such as skin related diseases, including but not limited to acne and psoriasis.

5-[PHENYL-TETRAHYDRONAPHTHALENE-2-YL DIHYDRONAPHTHALEN-2-YL AND HETEROARYL-CYCLOPROPYL]-PENTADIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY

Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of reducing serum thyroxine levels and transiently increasing triglyceride levels.

A new class of potent RAR antagonists: Dihydroanthracenyl, benzochromenyl and benzothiochromenyl retinoids

The synthesis and biological activity of a novel series of tricyclic retinoic acid receptor antagonists are described. These compounds bind with high affinity to the RARs and are potent antagonists of retinoid function in in vitro and in vivo systems.